About alector inc - ALEC
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
ALEC At a Glance
Alector, Inc.
131 Oyster Point Boulevard
South San Francisco, California 94080-2029
| Phone | 1-415-231-5660 | Revenue | 21.05M | |
| Industry | Biotechnology | Net Income | -142,929,000.00 | |
| Sector | Health Technology | Employees | 103 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ALEC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.635 |
| Price to Book Ratio | 5.617 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.434 |
| Enterprise Value to Sales | -2.809 |
| Total Debt to Enterprise Value | -0.613 |
ALEC Efficiency
| Revenue/Employee | 204,320.388 |
| Income Per Employee | -1,387,660.194 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.055 |
ALEC Liquidity
| Current Ratio | 3.834 |
| Quick Ratio | 3.834 |
| Cash Ratio | 3.684 |
ALEC Profitability
| Gross Margin | 54.094 |
| Operating Margin | -692.834 |
| Pretax Margin | -678.361 |
| Net Margin | -679.159 |
| Return on Assets | -37.537 |
| Return on Equity | -181.556 |
| Return on Total Capital | -213.703 |
| Return on Invested Capital | -131.112 |
ALEC Capital Structure
| Total Debt to Total Equity | 118.219 |
| Total Debt to Total Capital | 54.175 |
| Total Debt to Total Assets | 12.356 |
| Long-Term Debt to Equity | 87.478 |
| Long-Term Debt to Total Capital | 40.087 |